Literature DB >> 6786798

Quantitative determination of human plasma apolipoprotein A-I by laser immunonephelometry.

M Rosseneu, R Vercaemst, N Vinaimont, P Van Tornout, L O Henderson, P N Herbert.   

Abstract

A technical procedure is described for quantitation of human apolipoprotein A-I (apo A-I) in normal plasma or serum by immunonephelometry. Dilution of the plasma samples with 6 mol/L guanidine chloride ensures maximum exposure of the antigenic sites of the apoprotein and enables optimum quantitation of the apo A-I without requiring extraction with organic solvents. Similar data are obtained by this assay and with radioimmunoassay for normal subjects (1.2--1.5 g/L), and the results obtained on 31 patients are correlated with a coefficient of 0.92. The apo A-I values are correlated with values for plasma high-density lipoprotein cholesterol (r = 0.64). The interassay CV for immunonephelometry is about 7% and the standard curve is linear between 0.1 and 1.0 microgram of apo A-I per sample, corresponding to a 150-fold dilution of serum or plasma. The assay is applicable to plasma samples containing as much as 4 g of triglycerides per liter. At higher concentrations plasma delipidation is required.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6786798

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Immunoturbidimetric assays for serum apolipoproteins A1 and B using Cobas Bio centrifugal analyser.

Authors:  J N Mount; E M Kearney; M Rosseneu; B M Slavin
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

2.  Self-selected unrefined and refined carbohydrate diets do not affect metabolic control in pump-treated diabetic patients.

Authors:  A Venhaus; E Chantelau
Journal:  Diabetologia       Date:  1988-03       Impact factor: 10.122

3.  Influence of dietary factors on the plasma lipoprotein composition and content in neonates.

Authors:  J P Van Biervliet; M Rosseneu; H Caster
Journal:  Eur J Pediatr       Date:  1986-02       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.